

Jerome Ritz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/251704/publications.pdf>

Version: 2024-02-01

617
papers

50,408
citations

735

120
h-index

2127

203
g-index

632
all docs

632
docs citations

632
times ranked

36230
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 32.e1-32.e10.	1.2	7
2	Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. <i>Journal of Clinical Oncology</i> , 2022, 40, 189-201.	1.6	79
3	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. <i>Blood Advances</i> , 2022, 6, 2183-2194.	5.2	12
4	Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	16
5	BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. <i>Blood</i> , 2022, 139, 2983-2997.	1.4	6
6	Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML. <i>Blood</i> , 2022, 139, 3546-3557.	1.4	37
7	Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	48
8	Microbiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation. <i>JCI Insight</i> , 2022, 7, .	5.0	13
9	Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 4392-4402.	5.2	8
10	Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	44
11	Post-Transcriptional Genetic Silencing of <i>BCL11A</i> to Treat Sickle Cell Disease. <i>New England Journal of Medicine</i> , 2021, 384, 205-215.	27.0	250
12	Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. <i>Nature</i> , 2021, 590, 157-162.	27.8	53
13	Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2021, 5, 352-364.	5.2	58
14	NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100103.	4.0	32
15	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021, 137, 3212-3217.	1.4	24
16	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466.	1.2	24
17	Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias. <i>Nature Immunology</i> , 2021, 22, 520-529.	14.5	11
18	Comparative analysis of cell therapy infusion workflows at clinical sites. <i>Cytotherapy</i> , 2021, 23, 285-292.	0.7	5

#	ARTICLE	IF	CITATIONS
19	Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. <i>Med</i> , 2021, 2, 411-422.e5.	4.4	41
20	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. <i>Haematologica</i> , 2021, 106, 3219-3222.	3.5	15
21	Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. <i>Blood Advances</i> , 2021, 5, 5140-5149.	5.2	21
22	Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2021, 9, 1465-1475.	3.4	8
23	Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is Well-Tolerated, with Rapid Pharmacodynamic and Clinical Response in Newly Diagnosed Acute Graft-Versus-Host Disease. <i>Blood</i> , 2021, 138, 2891-2891.	1.4	0
24	Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. <i>Cell Reports</i> , 2021, 37, 109992.	6.4	37
25	Rejuvenated BCMA-Specific CD8 + Cytotoxic T Lymphocytes Derived from Antigen-Specific Induced Pluripotent Stem Cells : Immunotherapeutic Application in Multiple Myeloma. <i>Blood</i> , 2021, 138, 75-75.	1.4	0
26	Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1821-1823.	2.4	1
27	A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. <i>Bone Marrow Transplantation</i> , 2020, 55, 804-810.	2.4	3
28	Comparing the functionality of proleukin® and akron interleukin-2 through an analysis of key T cell subsets. <i>Cytotherapy</i> , 2020, 22, S121-S122.	0.7	0
29	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. <i>Journal of Clinical Oncology</i> , 2020, 38, 3095-3106.	1.6	216
30	Donor risk factors and recipient clinical impact of positive microbial contamination after bone marrow harvests - a large academic medical center experience. <i>Cytotherapy</i> , 2020, 22, S156-S157.	0.7	0
31	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. <i>Blood Advances</i> , 2020, 4, 4113-4123.	5.2	22
32	Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	17
33	Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1926-1932.	27.0	298
34	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , 2020, 135, 2182-2191.	1.4	62
35	BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 1881-1893.	5.2	16
36	Targeting the CD6-Alcam Pathway to Prevent and Treat Graft Vs Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S172.	2.0	0

#	ARTICLE	IF	CITATIONS
37	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020, 11, 2996.	12.8	98
38	T Cell Clonal Dynamics Determined by High-Resolution TCR- β Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1567-1574.	2.0	11
39	NK Cell Impairment after Haploidentical Allogeneic Hematopoietic Cell Transplant in Patients Receiving Post-Transplant Cyclophosphamide (PTCy). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S70-S71.	2.0	0
40	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. <i>Blood</i> , 2020, 135, 28-40.	1.4	14
41	PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 122-126.	5.2	46
42	Maturation and Phenotypic Heterogeneity of Human CD4+ Regulatory T Cells From Birth to Adulthood and After Allogeneic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 570550.	4.8	11
43	Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 608485.	4.8	4
44	Abstract LB-272: T-cell clonal dynamics determined by high resolution TCR- β sequencing in recipients of allogeneic hematopoietic cell transplantation. , 2020, , .		1
45	Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2020, 130, 4624-4636.	8.2	55
46	Engineered Memory-like NK Cells Targeting a Neopeptide Derived from Intracellular NPM1c Exhibit Potent Activity and Specificity Against Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 3-4.	1.4	8
47	<i>DNMT3A</i> clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2020, 136, 26-26.	1.4	5
48	Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 580328.	4.8	29
49	Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 34-35.	1.4	1
50	Cytokine-Induced Memory-like NK Cells Exhibit Massive Expansion and Long-Term Persistence after Infusion Post-Haploidentical Stem Cell Transplantation: A Report of the First Three Cases in a Phase I Trial. <i>Blood</i> , 2020, 136, 8-9.	1.4	4
51	Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itozumab. <i>Blood</i> , 2020, 136, 10-11.	1.4	1
52	Impact of IL-6R Blockade for Cytokine Release Syndrome in Haploidentical Donor Stem Cell Transplant Patients on Infections, Clinical Outcomes and Immune Reconstitution. <i>Blood</i> , 2020, 136, 12-13.	1.4	0
53	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. <i>Clinical Immunology</i> , 2019, 207, 18-23.	3.2	10
54	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials) Tj ETQq0 0 0 rgBT7Overlock 10 Tf 50 5	2.0	15

#	ARTICLE	IF	CITATIONS
55	T Cell and B Cell-Mediated Pathology in Chronic Graft-Versus-Host Disease. , 2019, , 251-273.		0
56	A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation. Haematologica, 2019, 104, e314-e317.	3.5	11
57	Single Cell T Cell Maps of Donor Lymphocyte Infusion (DLI) Response and Resistance. Biology of Blood and Marrow Transplantation, 2019, 25, S48.	2.0	0
58	Individual Patient Dose-Escalated Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease in Children and Adults: Safety, Efficacy and Immune Correlates. Biology of Blood and Marrow Transplantation, 2019, 25, S16-S17.	2.0	0
59	Making Room in the Parking Lot for More Cars - How Changes to Autologous Collection Targets for Patients with Multiple Myeloma Optimized Resource Utilization in the Apheresis Collection Center and Cell Storage Facility at Dana-Farber Cancer Institute. Biology of Blood and Marrow Transplantation. 2019. 25. S177-S178.	2.0	0
60	Genetic Predispositions, Management Strategies, and Clinical Outcomes in Adults with Hemophagocytic Lymphohistiocytosis (HLH) after Reduced-Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation (HSCT) at Dana-Farber Cancer Institute. Biology of Blood and Marrow Transplantation, 2019, 25, S398.	2.0	1
61	Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease. Frontiers in Immunology, 2019, 10, 334.	4.8	16
62	Clinical Metabolomics Identifies Blood Serum Branched Chain Amino Acids as Potential Predictive Biomarkers for Chronic Graft vs. Host Disease. Frontiers in Oncology, 2019, 9, 141.	2.8	18
63	Dynamics of Immune Cell Reconstitution in Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide (PTCy). Biology of Blood and Marrow Transplantation, 2019, 25, S327-S328.	2.0	1
64	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood, 2019, 134, 22-29.	1.4	129
65	Targeting PI3K function for amelioration of murine chronic graft-versus-host disease. American Journal of Transplantation, 2019, 19, 1820-1830.	4.7	9
66	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Advances, 2019, 3, 2550-2561.	5.2	44
67	Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Advances, 2019, 3, 984-994.	5.2	24
68	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Advances, 2019, 3, 2199-2204.	5.2	52
69	Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Advances, 2019, 3, 969-979.	5.2	32
70	Immunomodulatory therapy improves outcome in multiple myeloma patients with clonal hematopoiesis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e15.	0.4	1
71	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature, 2019, 565, 234-239.	27.8	956
72	Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunology Research, 2019, 7, 100-112.	3.4	220

#	ARTICLE	IF	CITATIONS
73	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2019, 133, 94-99.	1.4	21
74	Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease. <i>Blood</i> , 2019, 134, 5603-5603.	1.4	4
75	Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease. <i>Blood</i> , 2019, 134, 4517-4517.	1.4	1
76	Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease. <i>Blood</i> , 2019, 134, 4516-4516.	1.4	2
77	Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 1930-1930.	1.4	6
78	Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Hematology International</i> , 2019, 1, 201-204.	1.7	0
79	Abstract 3371: Mapping the evolution of T cell states during DLI response and resistance using single-cell data and computational tools. , 2019, , .		0
80	Longitudinal Changes in the Intestinal Microbiome Composition Following Gut Decontamination in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients: A Pilot Study. <i>Blood</i> , 2019, 134, 5665-5665.	1.4	1
81	Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 4486-4486.	1.4	2
82	Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL). <i>Blood</i> , 2019, 134, 516-516.	1.4	0
83	Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leukemia Undergoing Myeloablative Allogeneic Transplantation. <i>Blood</i> , 2019, 134, 263-263.	1.4	9
84	Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study. <i>Blood</i> , 2019, 134, 2015-2015.	1.4	3
85	Abstract 3371: Mapping the evolution of T cell states during DLI response and resistance using single-cell data and computational tools. , 2019, , .		0
86	Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S70-S71.	2.0	0
87	Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. <i>Haematologica</i> , 2018, 103, 522-530.	3.5	28
88	Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. <i>Journal of Neuro-Oncology</i> , 2018, 137, 269-278.	2.9	42
89	Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4 ⁺ and CD8 ⁺ T cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E686-E695.	7.1	51
90	A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1733-1740.	2.0	23

#	ARTICLE	IF	CITATIONS
91	Low-Dose Interleukin-2 Therapy Activates Circulating T Follicular Regulatory Cells (cTFR) and Suppresses Circulating T Follicular Helper Cells (cTFH) in Patients with Chronic Gvhd. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S72.	2.0	4
92	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. <i>Cancer Discovery</i> , 2018, 8, 216-233.	9.4	503
93	Prediction of Severe Acute Graft-Versus-Host Disease (GVHD) in Recipients of HLA Identical Hematopoietic Cell Transplantation (HCT) Using Donor Gene Expression Profiling. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S173-S174.	2.0	0
94	NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 1412-1416.	5.2	2
95	Developing a robust competency program for the GMP novel cell therapy laboratory in the cell manipulation core facility laboratory at Dana-Farber Cancer Institute, Boston. <i>Cytotherapy</i> , 2018, 20, S79.	0.7	0
96	Safety considerations in the generation of clinical grade autologous ips cell lines. <i>Cytotherapy</i> , 2018, 20, S21.	0.7	0
97	Personnel environmental monitoring during manufacture of manipulated cell therapy products. <i>Cytotherapy</i> , 2018, 20, S68.	0.7	3
98	Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. <i>Cytotherapy</i> , 2018, 20, 952-963.	0.7	49
99	Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2216-2223.	2.0	18
100	5-year performance data and robust flexibility of a computerized physician ordering system for collection, processing, and administration of cellular therapy products. <i>Cytotherapy</i> , 2018, 20, S17-S18.	0.7	0
101	How optimizing efficiency for autologous stem cell collection can set the stage for novel cell therapy growth in multiple departments. <i>Cytotherapy</i> , 2018, 20, S73-S74.	0.7	0
102	Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2344-2353.	2.0	37
103	Biomanufacturing for clinically advanced cell therapies. <i>Nature Biomedical Engineering</i> , 2018, 2, 362-376.	22.5	127
104	Abstract 2954: Immunomodulator maintenance post autologous stem cell transplant predicts better outcome in multiple myeloma patients with clonal hematopoiesis of indeterminate potential. , 2018, , .		3
105	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018, 132, 749-749.	1.4	6
106	PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 1650-1650.	1.4	2
107	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 706-706.	1.4	3
108	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem-Cell Transplantation: A Post-Hoc Analysis of a Randomized Controlled Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate (BMT CTN 0402). <i>Blood</i> , 2018, 132, 2110-2110.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Flipping the Switch: Initial Results of Genetic Targeting of the Fetal to Adult Globin Switch in Sickle Cell Patients. <i>Blood</i> , 2018, 132, 1023-1023.	1.4	15
110	Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity. <i>Blood</i> , 2018, 132, 92-92.	1.4	74
111	Mass Cytometry Identifies T Cell Populations Associated with Severe Hepatotoxicity in CLL Patients on Upfront Idelalisib. <i>Blood</i> , 2018, 132, 4413-4413.	1.4	2
112	Abstract 5631: Personal neoantigen-targeting vaccination generates neoepitope-specific T cell responses in tumors of patients with glioblastoma. <i>Cancer Research</i> , 2018, 78, 5631-5631.	0.9	5
113	Low-Dose Interleukin-2 Therapy Enhances Cytotoxicity of CD56bright NK Cells in Patients with Chronic Gvhd. <i>Blood</i> , 2018, 132, 606-606.	1.4	4
114	Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2018, 132, 817-817.	1.4	0
115	Mapping the Evolution of T Cell Transcriptional States during DLI Response and Resistance Using Single-Cell Data. <i>Blood</i> , 2018, 132, 821-821.	1.4	0
116	Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 820-820.	1.4	0
117	Profiling T Cell Receptor Repertoires in Phase I/II Clinical Trials of Donor Treg Infusion for the Treatment of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2018, 132, 4563-4563.	1.4	0
118	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1598-1605.	1.6	339
119	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. <i>Blood</i> , 2017, 129, 1380-1388.	1.4	209
120	Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. <i>Cancer</i> , 2017, 123, 2642-2650.	4.1	67
121	Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2017, 23, 3510-3519.	7.0	130
122	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. <i>Blood</i> , 2017, 129, 2186-2197.	1.4	156
123	Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF- β production. <i>Blood</i> , 2017, 129, 2570-2580.	1.4	122
124	Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 852-867.	9.4	132
125	Research Techniques Made Simple: Mass Cytometry Analysis Tools for Decrypting the Complexity of Biological Systems. <i>Journal of Investigative Dermatology</i> , 2017, 137, e43-e51.	0.7	13
126	Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. <i>Blood</i> , 2017, 130, 91-94.	1.4	78

#	ARTICLE	IF	CITATIONS
127	Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease. <i>Blood</i> , 2017, 129, 3256-3261.	1.4	34
128	Research Techniques Made Simple: Experimental Methodology for Single-Cell Mass Cytometry. <i>Journal of Investigative Dermatology</i> , 2017, 137, e31-e38.	0.7	19
129	Mechanistic approaches for the prevention and treatment of chronic GVHD. <i>Blood</i> , 2017, 129, 22-29.	1.4	98
130	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. <i>Cytotherapy</i> , 2017, 19, 272-284.	0.7	13
131	Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 2889-2899.	1.4	17
132	An immunogenic personal neoantigen vaccine for patients with melanoma. <i>Nature</i> , 2017, 547, 217-221.	27.8	2,112
133	Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 103-112.	2.0	4
134	Antibiotic-mediated modification of the intestinal microbiome in allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 183-190.	2.4	50
135	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 211-234.	2.0	328
136	Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. <i>Blood Advances</i> , 2017, 1, 2269-2279.	5.2	16
137	Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti- α T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4011.	1.6	258
138	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. <i>JCI Insight</i> , 2017, 2, .	5.0	53
139	Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. <i>JCI Insight</i> , 2016, 1, e89278.	5.0	126
140	Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34 ⁺ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2016, 101, 499-505.	3.5	43
141	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. <i>Blood</i> , 2016, 127, 2144-2154.	1.4	145
142	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	16.8	227
143	Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. <i>Blood</i> , 2016, 127, 646-657.	1.4	145
144	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. <i>Blood</i> , 2016, 128, 130-137.	1.4	176

#	ARTICLE	IF	CITATIONS
145	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016, 128, 195-203.	1.4	259
146	A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2016, 101, 1251-1259.	3.5	27
147	Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. <i>British Journal of Haematology</i> , 2016, 175, 841-850.	2.5	47
148	CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice. <i>Immunity</i> , 2016, 45, 209-223.	14.3	73
149	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. <i>Blood</i> , 2016, 127, 2489-2497.	1.4	92
150	Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. <i>Blood</i> , 2016, 128, 1013-1017.	1.4	95
151	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2016, 375, 143-153.	27.0	488
152	Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes. <i>Haematologica</i> , 2016, 101, e30-e33.	3.5	5
153	Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 355-366.	4.2	13
154	Dramatic Expansion of HSCs: New Possibilities for HSC Transplants?. <i>Cell Stem Cell</i> , 2016, 18, 10-12.	11.1	29
155	Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma. <i>Blood</i> , 2016, 128, 4052-4052.	1.4	32
156	A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti-T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2016, 128, 505-505.	1.4	12
157	All-Trans Retinoic Acid (ATRA) Targets IRF4 Deficient, NOTCH2-Activated B Cells from Chronic Gvhd Patients. <i>Blood</i> , 2016, 128, 669-669.	1.4	1
158	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 986-986.	1.4	3
159	Bortezomib-Based Versus Standard of Care Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation: A Phase II Randomized Controlled Trial. <i>Blood</i> , 2016, 128, 508-508.	1.4	3
160	BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 3425-3425.	1.4	0
161	Donor Chip Causes Donor-Derived Clonal Hematopoiesis As an Early Complication of Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 987-987.	1.4	0
162	TREG and Tcon Dynamics after Allo-HSCT: CgvhD Is Associated to Decreased Na ⁺ Ve and Stem Cell Memory Subsets with a Concomitant Increase in Terminally Differentiated T Cell Subsets. <i>Blood</i> , 2016, 128, 2229-2229.	1.4	4

#	ARTICLE	IF	CITATIONS
163	Functional Effects of Low-Dose IL-2 in Patients with Chronic Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 667-667.	1.4	4
164	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 4085-4094.	1.4	101
165	Aberrant B-cell homeostasis in chronic GVHD. <i>Blood</i> , 2015, 125, 1703-1707.	1.4	107
166	Reconstitution of T Cell Immunity after Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1151-1152.	2.0	1
167	Reprint of: B Cells in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S11-S18.	2.0	4
168	A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1907-1913.	2.0	27
169	Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 873-880.	2.0	56
170	Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. <i>Clinical Cancer Research</i> , 2015, 21, 3178-3186.	7.0	34
171	Interferon- β -induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. <i>Oncotmunology</i> , 2015, 4, e1008824.	4.6	238
172	Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions. <i>Clinical Cancer Research</i> , 2015, 21, 1010-1018.	7.0	11
173	B Cells in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 16-23.	2.0	86
174	PD-1 Signaling Has a Critical Role in Maintaining Regulatory T Cell Homeostasis; Implication for Treg Depletion Therapy By PD-1 Blockade. <i>Blood</i> , 2015, 126, 848-848.	1.4	10
175	IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. <i>PLoS ONE</i> , 2015, 10, e0132564.	2.5	22
176	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 4867-4876.	8.2	173
177	Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/ β -catenin pathway and alters immune reconstitution after UCBT. <i>Blood Cancer Journal</i> , 2014, 4, e178-e178.	6.2	29
178	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1499-1508.	3.5	15
179	Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2014, 89, 404-409.	4.1	46
180	Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 453-462.	1.4	286

#	ARTICLE	IF	CITATIONS
181	Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 2691-2698.	1.6	359
182	White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. <i>American Journal of Hematology</i> , 2014, 89, 591-597.	4.1	19
183	Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2014, 89, 1092-1096.	4.1	17
184	Current issues in chronic graft-versus-host disease. <i>Blood</i> , 2014, 124, 374-384.	1.4	336
185	A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1737-1743.	2.0	48
186	Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 668-675.	2.0	45
187	A Modified $\hat{3}$ -Retrovirus Vector for X-Linked Severe Combined Immunodeficiency. <i>New England Journal of Medicine</i> , 2014, 371, 1407-1417.	27.0	358
188	Recipient T-Cell Repertoire Diversity after Double Umbilical Cord Transplantation Correlates with Non-Relapse Mortality and Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S243-S244.	2.0	3
189	Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: Mechanism, function, and implication for a potential novel therapeutic target. <i>Experimental Hematology</i> , 2014, 42, 307-316.e8.	0.4	29
190	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. <i>Blood</i> , 2014, 123, 3988-3998.	1.4	179
191	Donor Chimerism Early after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1516-1521.	2.0	50
192	Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. <i>Blood</i> , 2014, 123, 1412-1421.	1.4	78
193	Quantitative and Qualitative Immune Reconstitution Following Umbilical Cord Blood Transplantation. <i>Pancreatic Islet Biology</i> , 2014, , 133-152.	0.3	0
194	Prognostic Value of TREC, IL-7 and SCF Levels on Clinical Outcomes after Double Umbilical Cord Blood Transplantation in Adults. <i>Blood</i> , 2014, 124, 2488-2488.	1.4	0
195	Enhanced Expression of PD-1 Modulates CD4 ⁺ Foxp3 ⁺ Regulatory T Cell Homeostasis during Low-Dose IL-2 Therapy in Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2014, 124, 662-662.	1.4	0
196	Sequencing-Based Detection of Minimal Residual Disease Is Associated with Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Lymphoid Malignancies. <i>Blood</i> , 2014, 124, 3961-3961.	1.4	0
197	Low-Dose IL-2 Reduces Mitochondrial Priming and Increases Bcl2 Expression in CD4 Memory Regulatory T Cells. <i>Blood</i> , 2014, 124, 1414-1414.	1.4	0
198	ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death. <i>New England Journal of Medicine</i> , 2013, 369, 529-539.	27.0	339

#	ARTICLE	IF	CITATIONS
199	Phase I Study of Alemtuzumab for Therapy of Steroid-Refractory Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 804-811.	2.0	18
200	Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. <i>Respiratory Medicine</i> , 2013, 107, 276-283.	2.9	18
201	B and T cells in chronic graft-versus-host disease and graft-versus-leukemia. , 2013, , 299-326.		0
202	Expression of $\alpha 4 \beta 7$ integrin on memory CD8+ T cells at the presentation of acute intestinal GVHD. <i>Bone Marrow Transplantation</i> , 2013, 48, 598-603.	2.4	22
203	Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT correlate with the development of chronic GVHD. <i>Bone Marrow Transplantation</i> , 2013, 48, 593-597.	2.4	51
204	Probing circulating tumor cells in microfluidics. <i>Lab on A Chip</i> , 2013, 13, 602.	6.0	156
205	A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Haematologica</i> , 2013, 98, 964-970.	3.5	11
206	KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2013, 48, 1000-1002.	2.4	26
207	Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease. <i>Science Translational Medicine</i> , 2013, 5, 179ra43.	12.4	401
208	Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. <i>Leukemia</i> , 2013, 27, 362-369.	7.2	95
209	Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. <i>Blood</i> , 2013, 122, 3074-3081.	1.4	280
210	Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. <i>Blood</i> , 2013, 122, 1510-1517.	1.4	104
211	Tregs, HSCT, and acute GVHD: up close and personal. <i>Blood</i> , 2013, 122, 1690-1691.	1.4	12
212	Identification of Cytolytic CD161 ^{hi} CD56 ⁺ Regulatory CD8 T Cells in Human Peripheral Blood. <i>PLoS ONE</i> , 2013, 8, e59545.	2.5	21
213	Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. <i>Journal of Clinical Investigation</i> , 2013, 123, 3756-3765.	8.2	69
214	Low-Dose IL-2 Induces Bcl2 Expression and Resistance To Apoptosis In CD4 Regulatory T Cells. <i>Blood</i> , 2013, 122, 3475-3475.	1.4	1
215	Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients. <i>Blood</i> , 2013, 122, 695-695.	1.4	3
216	Role of B Cells in Graft-Versus-Leukemia and Graft-Versus-Host Disease. <i>Blood</i> , 2013, 122, SCI-3-SCI-3.	1.4	1

#	ARTICLE	IF	CITATIONS
217	Reconstitution Of EBV-Specific Immunity In Adult Recipients Of Double Cord Blood Transplantation Depends On SCF and IL-7 Levels and Maintenance Of a Diverse TCR Repertoire. <i>Blood</i> , 2013, 122, 3302-3302.	1.4	0
218	A Bortezomib-Based Regimen Offers Excellent Outcomes In Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: Phase II Results. <i>Blood</i> , 2013, 122, 3335-3335.	1.4	9
219	JAK1 and JAK2 Modulate Tumor Cell Susceptibility To Natural Killer (NK) Cells Through Regulation Of PDL1 Expression. <i>Blood</i> , 2013, 122, 3472-3472.	1.4	2
220	Developing Novel Approaches To Comprehensively Assess T Cell Repertoire Dynamics In The Early Post-Transplant Period. <i>Blood</i> , 2013, 122, 4618-4618.	1.4	0
221	Bortezomib-Based Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 3202-3208.	1.6	135
222	Detecting T-cell reactivity to whole cell vaccines. <i>Oncolmmunology</i> , 2012, 1, 1095-1103.	4.6	14
223	Development and Implementation of a Computerized System for Collection, Processing, and Administration of Cellular Therapy Products. <i>Journal of Oncology Practice</i> , 2012, 8, 262-266.	2.5	0
224	Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2012, 119, 3142-3150.	1.4	11
225	Expression of CD30 in patients with acute graft-versus-host disease. <i>Blood</i> , 2012, 120, 691-696.	1.4	47
226	A disease risk index for patients undergoing allogeneic stem cell transplantation. <i>Blood</i> , 2012, 120, 905-913.	1.4	310
227	B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. <i>Blood</i> , 2012, 120, 2529-2536.	1.4	126
228	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. <i>Blood</i> , 2012, 119, 1570-1580.	1.4	221
229	Immune Reconstitution after Double Umbilical Cord Blood Stem Cell Transplantation: Comparison with Unrelated Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 565-574.	2.0	160
230	Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 805-812.	2.0	79
231	A clonal model for human CD8 ⁺ regulatory T cells: Unrestricted contact-dependent killing of activated CD4 ⁺ T cells. <i>European Journal of Immunology</i> , 2012, 42, 69-79.	2.9	9
232	Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. <i>Journal of Clinical Investigation</i> , 2012, 122, 2369-2383.	8.2	32
233	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 311-311.	1.4	3
234	Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012, 120, 1892-1892.	1.4	0

#	ARTICLE	IF	CITATIONS
235	Impact of White Blood Cell Count Recovery On Clinical Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4136-4136.	1.4	0
236	Targeting the Interferon- γ (IFN- γ) Pathway to Enhance Susceptibility of Multiple Myeloma Tumor Cells to NK Cell Lysis. <i>Blood</i> , 2012, 120, 4013-4013.	1.4	0
237	Plasma ST2 Concentrations Predict Development of Acute Gvhd and Non-Relapse Mortality. <i>Blood</i> , 2012, 120, 466-466.	1.4	0
238	Enhancement of Tumor Cell Susceptibility to NK Cell Activity Through Inhibition of the PI3K Signaling Pathway. <i>Blood</i> , 2012, 120, 2152-2152.	1.4	0
239	Reversal of T Cell Exhaustion in Pre-Treatment Marrow T Cells Is Associated with Effective Graft-Versus-Leukemia Responses to Donor Lymphocyte Infusion. <i>Blood</i> , 2012, 120, 1903-1903.	1.4	0
240	Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2011, 365, 2055-2066.	27.0	996
241	Immune Reconstitution After Double Umbilical Cord Blood Stem Cell Transplantation: Comparison With Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S233.	2.0	2
242	Use of Matched Unrelated Donors Compared with Matched Related Donors Is Associated with Lower Relapse and Superior Progression-Free Survival after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1196-1204.	2.0	57
243	Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. <i>Blood</i> , 2011, 118, 5021-5030.	1.4	44
244	Preclinical regulatory validation of an engineered diaphragmatic tendon made with amniotic mesenchymal stem cells. <i>Journal of Pediatric Surgery</i> , 2011, 46, 57-61.	1.6	73
245	Combined CD4 T-Cell and Antibody Response to Human Minor Histocompatibility Antigen DBY After Allogeneic Stem-Cell Transplantation. <i>Transplantation</i> , 2011, 92, 359-365.	1.0	19
246	Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. <i>Blood</i> , 2011, 117, 2275-2283.	1.4	115
247	Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. <i>Blood</i> , 2011, 117, 4315-4322.	1.4	75
248	Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. <i>Blood</i> , 2011, 118, 6691-6697.	1.4	180
249	Time to put the CAR-T before the horse. <i>Blood</i> , 2011, 118, 4761-4762.	1.4	11
250	Validation of short-term handling and storage conditions for marrow and peripheral blood stem cell products. <i>Transfusion</i> , 2011, 51, 137-147.	1.6	35
251	The elusive nature and function of mesenchymal stem cells. <i>Nature Reviews Molecular Cell Biology</i> , 2011, 12, 126-131.	37.0	544
252	Response to Helsby and Tingle. <i>American Journal of Hematology</i> , 2011, 86, 384-384.	4.1	1

#	ARTICLE	IF	CITATIONS
253	Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. <i>Bone Marrow Transplantation</i> , 2011, 46, 659-667.	2.4	104
254	Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. <i>Journal of Clinical Investigation</i> , 2011, 121, 1574-1584.	8.2	17
255	Donor B-Cell Alloantibody Deposition and Germinal Center Formation Are Required for the Development of Murine Chronic Gvhd and Bronchiolitis Obliterans. <i>Blood</i> , 2011, 118, 307-307.	1.4	1
256	FT1050 (16,16-dimethyl Prostaglandin E2)-Enhanced Umbilical Cord Blood Accelerates Hematopoietic Engraftment After Reduced Intensity Conditioning and Double Umbilical Cord Blood Transplantation. <i>Blood</i> , 2011, 118, 653-653.	1.4	11
257	MicroRNA Expression Profiling Identifies Activated B Cell Status in Chronic Lymphocytic Leukemia Cells. <i>PLoS ONE</i> , 2011, 6, e16956.	2.5	69
258	Patterns of B Cell Activating Factor (BAFF) Levels, B Cell Recovery, and BAFF/B Cell Ratios Correlate with the Development of Chronic Graft-Versus-Host Disease (cGVHD) Following Hematopoietic Stem Cell Transplantation (HSCT). <i>Blood</i> , 2011, 118, 3036-3036.	1.4	0
259	JAK1 and JAK2 Modulate Myeloma Cell Susceptibility to NK Cells Through the Interferon Gamma (IFN- γ) Pathway,. <i>Blood</i> , 2011, 118, 3960-3960.	1.4	0
260	Immune Reconstitution After Cord Blood Transplantation in Adults Depends on Activity of Thymic Epithelial Cells and Vascular Endothelial Elements,. <i>Blood</i> , 2011, 118, 4075-4075.	1.4	0
261	Ex Vivo Expansion of Donor-Derived Anti-Tumor T Cells for CLL-Specific Adoptive Immunotherapy. <i>Blood</i> , 2011, 118, 978-978.	1.4	0
262	KIR-Ligand Incompatibility Is Not Associated with Relapse Reduction After Double Umbilical Cord Blood Transplantation,. <i>Blood</i> , 2011, 118, 4150-4150.	1.4	11
263	B-cell-directed therapy for chronic graft-versus-host disease. <i>Haematologica</i> , 2010, 95, 1811-1813.	3.5	11
264	Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. <i>Blood</i> , 2010, 115, 4111-4119.	1.4	107
265	Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2010, 85, 967-971.	4.1	19
266	Graft-versus-Leukemia Antigen CML66 Elicits Coordinated B-Cell and T-Cell Immunity after Donor Lymphocyte Infusion. <i>Clinical Cancer Research</i> , 2010, 16, 2729-2739.	7.0	37
267	Serologic Markers of Effective Tumor Immunity against Chronic Lymphocytic Leukemia Include Nonmutated B-Cell Antigens. <i>Cancer Research</i> , 2010, 70, 1344-1355.	0.9	31
268	Diverse Patterns of T-Cell Response against Multiple Newly Identified Human Y Chromosome-Encoded Minor Histocompatibility Epitopes. <i>Clinical Cancer Research</i> , 2010, 16, 1642-1651.	7.0	33
269	Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 252-257.	7.1	314
270	Efficacious Immune Therapy in Chronic Myelogenous Leukemia (CML) Recognizes Antigens That Are Expressed on CML Progenitor Cells. <i>Cancer Research</i> , 2010, 70, 906-915.	0.9	52

#	ARTICLE	IF	CITATIONS
271	Current Challenges in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, S146-S151.	2.0	40
272	Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced Age. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 792-800.	2.0	76
273	NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 565-586.	2.0	107
274	Prediction of Venous Occlusive Disease Using Biomarkers of Endothelial Injury. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1180-1185.	2.0	85
275	Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. <i>Journal of Clinical Investigation</i> , 2010, 120, 1479-1493.	8.2	212
276	Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 15825-15830.	7.1	105
277	Revealing Tumor Immunity after Hematopoietic Stem Cell Transplantation. <i>Clinical Cancer Research</i> , 2009, 15, 4515-4517.	7.0	8
278	Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. <i>Nature Genetics</i> , 2009, 41, 1341-1344.	21.4	91
279	Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. <i>Blood</i> , 2009, 114, 3956-3959.	1.4	86
280	Combined CD4+ Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3+ Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 382-388.	2.0	58
281	Up-Regulation of $\alpha 4 \beta 7$ Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1066-1076.	2.0	45
282	Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 1062-1069.e4.	2.9	42
283	Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. <i>Blood</i> , 2009, 113, 1681-1688.	1.4	33
284	Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. <i>Blood</i> , 2009, 113, 3865-3874.	1.4	285
285	Graft-Versus-Leukemia Antigen CML66 Elicits Coordinated B and T Cell Immunity After Donor Lymphocyte Infusion. <i>Blood</i> , 2009, 114, 2449-2449.	1.4	0
286	Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. <i>American Journal of Hematology</i> , 2008, 83, 771-777.	4.1	18
287	Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. <i>Experimental Hematology</i> , 2008, 36, 1205-1215.	0.4	10
288	Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 122, 1185-1193.	2.9	35

#	ARTICLE	IF	CITATIONS
289	Preclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell manufacturing protocol. <i>Journal of Pediatric Surgery</i> , 2008, 43, 1164-1169.	1.6	61
290	A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 28-35.	2.0	57
291	MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 1285-1290.	7.1	235
292	Targets of Tumor Immunity After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Cancer Research</i> , 2008, 14, 4997-4999.	7.0	16
293	Autologous Peripheral Blood Stem Cell Products from Patients with Hematologic Malignancies Have Increased Frequency of Regulatory T Cells (CD4+FoxP3+ Treg).. <i>Blood</i> , 2008, 112, 2310-2310.	1.4	1
294	Novel Myeloma-Associated Antigens Revealed in the Context of Successful Syngeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 815-815.	1.4	1
295	Genetic Screening for Myeloma Cell Susceptibility to NK Cell Mediated Lysis Using Large Lentiviral shRNA Libraries. <i>Blood</i> , 2008, 112, 2900-2900.	1.4	1
296	Development of CMV-SPECIFIC Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of NAïVE CD8+ T Cells. <i>Blood</i> , 2008, 112, 1167-1167.	1.4	0
297	Diverse Patterns of T Cell Reactivity Directed against Multiple Y Chromosome-Derived, HLA a*0201 Restricted, Peptides in Patients with chronic Gvhd. <i>Blood</i> , 2008, 112, 464-464.	1.4	0
298	High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease. <i>Clinical Cancer Research</i> , 2007, 13, 6107-6114.	7.0	238
299	Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. <i>Blood</i> , 2007, 109, 2001-2007.	1.4	14
300	Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 655-664.	2.0	135
301	Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2007, 109, 1355-1362.	1.4	93
302	Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis. <i>Haematologica</i> , 2007, 92, 619-626.	3.5	12
303	Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. <i>British Journal of Haematology</i> , 2007, 139, 504-507.	2.5	52
304	Chronic GVHD Is Associated with a BAFF Driven BCR-Activated B Cell Repertoire.. <i>Blood</i> , 2007, 110, 166-166.	1.4	1
305	CD34+ CD38 ⁺ and CD34+ HLA-DR ⁺ cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation. <i>Cytotherapy</i> , 2006, 8, 399-407.	0.7	20
306	Impact of Conditioning Regimen Intensity on Outcome of Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1047-1055.	2.0	181

#	ARTICLE	IF	CITATIONS
307	Predictors of Improved Progression-Free Survival After Nonmyeloablative Allogeneic Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1056-1064.	2.0	110
308	ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications. <i>Blood</i> , 2006, 107, 197-204.	1.4	30
309	SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. <i>Blood</i> , 2006, 108, 2726-2735.	1.4	194
310	IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. <i>Blood</i> , 2006, 108, 1571-1579.	1.4	651
311	Induction of Tumor Immunity Following Allogeneic Stem Cell Transplantation. <i>Advances in Immunology</i> , 2006, 90, 133-173.	2.2	72
312	Studying Human Regulatory T Cells In vivo: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 5265-5267.	7.0	6
313	Rituximab for steroid-refractory chronic graft-versus-host disease. <i>Blood</i> , 2006, 108, 756-762.	1.4	422
314	Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.. <i>Blood</i> , 2006, 108, 259-259.	1.4	1
315	Effective Graft-Versus-Leukemia Responses Are Associated with the Presence of Nucleic Acid-Immunoglobulin Complexes That Stimulate TLR8 and TLR9.. <i>Blood</i> , 2006, 108, 188-188.	1.4	0
316	Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. <i>Blood</i> , 2005, 105, 1810-1814.	1.4	280
317	Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. <i>Blood</i> , 2005, 105, 2973-2978.	1.4	361
318	Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. <i>Blood</i> , 2005, 105, 3945-3950.	1.4	94
319	Evidence for ineffective erythropoiesis in severe sickle cell disease. <i>Blood</i> , 2005, 106, 3639-3645.	1.4	79
320	Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. <i>Blood</i> , 2005, 106, 4389-4396.	1.4	208
321	Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. <i>Blood</i> , 2005, 106, 2903-2911.	1.4	430
322	FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia. <i>British Journal of Haematology</i> , 2005, 130, 43-50.	2.5	16
323	Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression. <i>Clinical and Experimental Immunology</i> , 2005, 141, 326-332.	2.6	89
324	Bayesian Error-in-Variable Survival Model for the Analysis of GeneChip Arrays. <i>Biometrics</i> , 2005, 61, 488-497.	1.4	17

#	ARTICLE	IF	CITATIONS
325	Gene Expression Profiles of B-lineage Adult Acute Lymphocytic Leukemia Reveal Genetic Patterns that Identify Lineage Derivation and Distinct Mechanisms of Transformation. <i>Clinical Cancer Research</i> , 2005, 11, 7209-7219.	7.0	128
326	Graft-versus-Leukemia Target Antigens in Chronic Myelogenous Leukemia Are Expressed on Myeloid Progenitor Cells. <i>Clinical Cancer Research</i> , 2005, 11, 4504-4511.	7.0	54
327	Rituxan for steroid-refractory chronic GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 10-11.	2.0	3
328	Pre-Infusion Characteristics of the Predominant Cord Blood Unit Correlate with Hematopoietic Engraftment in the Setting of Non-Myeloablative Double Cord Blood Transplant (DCBT).. <i>Blood</i> , 2005, 106, 3027-3027.	1.4	3
329	Post-Transplant Monitoring of Erythroid Lineage Specific Chimerism.. <i>Blood</i> , 2005, 106, 5233-5233.	1.4	0
330	Detection of the NUP214-ABL Rearrangement in T-ALL by High-Density Oligonucleotide Arrays: Evidence of the Value of This Approach in the Identification of Gene Amplifications.. <i>Blood</i> , 2005, 106, 1211-1211.	1.4	0
331	Identification of Target Antigens Recognized in MGUS for Immunotherapeutic Approaches.. <i>Blood</i> , 2005, 106, 3463-3463.	1.4	0
332	Patients Who Respond to Donor Lymphocyte Infusion (DLI) Have an Antibody Response Against PDC-E2, the Immunodominant Autoantigens of Primary Biliary Cirrhosis (PBC), but with Different Specificity.. <i>Blood</i> , 2005, 106, 3105-3105.	1.4	3
333	Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation. <i>Clinical Cancer Research</i> , 2004, 10, 5065-5071.	7.0	72
334	Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation. <i>Journal of Experimental Medicine</i> , 2004, 199, 1133-1142.	8.5	162
335	A Novel Mechanism of Alternative Promoter and Splicing Regulates the Epitope Generation of Tumor Antigen CML66-L. <i>Journal of Immunology</i> , 2004, 172, 651-660.	0.8	37
336	Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. <i>Blood</i> , 2004, 103, 2771-2778.	1.4	296
337	Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. <i>Transfusion</i> , 2004, 44, 253-261.	1.6	13
338	Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. <i>Blood</i> , 2004, 103, 353-359.	1.4	149
339	Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. <i>Blood</i> , 2004, 103, 656-663.	1.4	73
340	Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2004, 104, 1224-1226.	1.4	140
341	Mixed Chimerism Following Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease Prevents Intravascular Hemolysis and Restores Endothelial Function.. <i>Blood</i> , 2004, 104, 1679-1679.	1.4	8
342	Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.. <i>Blood</i> , 2004, 104, 2251-2251.	1.4	2

#	ARTICLE	IF	CITATIONS
343	The Y-Specific Gene PRY Is Expressed in Normal Blood Cells as Well as Leukemia Cells and Can Elicit a Specific Antibody Response in Male Recipients of Hematopoietic Stem Cells from Female Donors.. Blood, 2004, 104, 4976-4976.	1.4	0
344	PDC-E2, a Common Auto Antigen in Primary Biliary Cirrhosis (PBC) Is Also a Target of an Antibody Response in Patients Who Achieve Complete Remission after Donor Lymphocyte Infusion.. Blood, 2004, 104, 2121-2121.	1.4	0
345	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. Blood, 2004, 104, 185-185.	1.4	0
346	Identification of a LOH Region on Chromosome 9p Associated with a Specific Gene Expression Signature in Adult B-Lineage ALL through Integration of High Density Microarray Expression and SNP Analyses.. Blood, 2004, 104, 1119-1119.	1.4	0
347	Allogeneic B Cell Response to H-Y Minor Histocompatibility Antigens after Donor Lymphocyte Infusion Correlates with Disease Response.. Blood, 2004, 104, 296-296.	1.4	0
348	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. Blood, 2004, 104, 300-300.	1.4	2
349	ZAP-70 Expression in Acute Lymphoblastic Leukemia: Association with the E2A/PBX1 Rearrangement and with the Pre-B Stage of Differentiation.. Blood, 2004, 104, 4305-4305.	1.4	0
350	Sources and sequelae of bacterial contamination of hematopoietic stem cell components: implications for the safety of hematotherapy and graft engineering. Transfusion, 2003, 36, 782-788.	1.6	69
351	Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Experimental Hematology, 2003, 31, 924-933.	0.4	27
352	Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution. Transfusion, 2003, 43, 614-621.	1.6	17
353	Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplantation, 2003, 32, 1145-1151.	2.4	65
354	A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. Blood, 2003, 101, 363-369.	1.4	72
355	Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Research, 2003, 63, 2561-8.	0.9	32
356	ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6919-6924.	7.1	45
357	Human acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptors. Blood, 2002, 99, 4634-4637.	1.4	14
358	Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood, 2002, 99, 4610-4617.	1.4	78
359	Quantitative Monitoring of BCR / ABL Transcript During STI-571 Therapy. Leukemia and Lymphoma, 2002, 43, 2281-2289.	1.3	14
360	Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biology of Blood and Marrow Transplantation, 2002, 8, 625-632.	2.0	107

#	ARTICLE	IF	CITATIONS
361	Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 139-144.	2.0	33
362	ALLOGENEIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA. <i>Reviews in Clinical and Experimental Hematology</i> , 2002, 6, 205-224.	0.1	14
363	Synergistic Enhancement of Cell-Mediated Immunity by Interleukin-12 Plus Interleukin-2: Basis for Therapy of Cutaneous T Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2002, 118, 366-371.	0.7	27
364	Adult hematopoietic stem cell plasticity. <i>Transfusion</i> , 2002, 42, 1096-1101.	1.6	11
365	Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2002, 117, 828-834.	2.5	131
366	CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. <i>Cancer Research</i> , 2002, 62, 5517-5522.	0.9	68
367	Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. <i>Clinical Cancer Research</i> , 2002, 8, 2052-60.	7.0	45
368	CD6+ Donor Marrow T-Cell Depletion as the Sole Form of Graft-Versus-Host Disease Prophylaxis in Patients Undergoing Allogeneic Bone Marrow Transplant From Unrelated Donors. <i>Journal of Clinical Oncology</i> , 2001, 19, 1152-1159.	1.6	49
369	A CD4+ T CELL CLONE SELECTED FROM A CML PATIENT AFTER DONOR LYMPHOCYTE INFUSION RECOGNIZES BCR-ABL BREAKPOINT PEPTIDES BUT NOT TUMOR CELLS1. <i>Transplantation</i> , 2001, 71, 1131-1137.	1.0	18
370	Specific down-regulation of interleukin-12 signaling through induction of phospho-STAT4 protein degradation. <i>Blood</i> , 2001, 97, 3860-3866.	1.4	34
371	Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. <i>Blood</i> , 2001, 98, 1116-1121.	1.4	107
372	T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. <i>Blood</i> , 2001, 98, 934-939.	1.4	193
373	CD2 stimulation leads to the delayed and prolonged activation of STAT1 in T cells but not NK cells. <i>Experimental Hematology</i> , 2001, 29, 209-220.	0.4	14
374	CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 7492-7497.	7.1	99
375	Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. <i>Bone Marrow Transplantation</i> , 2000, 25, 623-632.	2.4	63
376	Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. <i>Blood</i> , 2000, 95, 352-359.	1.4	138
377	Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. <i>Blood</i> , 2000, 95, 3183-3190.	1.4	177
378	Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 375-386.	2.0	61

#	ARTICLE	IF	CITATIONS
379	Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. <i>Journal of Clinical Investigation</i> , 2000, 106, 705-714.	8.2	121
380	Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. <i>Blood</i> , 2000, 95, 352-359.	1.4	11
381	Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. <i>Blood</i> , 2000, 95, 3183-3190.	1.4	10
382	Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. <i>Blood</i> , 2000, 95, 3183-90.	1.4	77
383	Comparative Outcomes of T-Cellâ€Depleted and Nonâ€T-Cellâ€Depleted Allogeneic Bone Marrow Transplantation for Chronic Myelogenous Leukemia: Impact of Donor Lymphocyte Infusion. <i>Journal of Clinical Oncology</i> , 1999, 17, 561-561.	1.6	108
384	Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 3128-3135.	1.6	180
385	Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma. <i>Blood</i> , 1999, 94, 3325-3333.	1.4	319
386	PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. <i>Human Molecular Genetics</i> , 1999, 8, 185-193.	2.9	254
387	CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. <i>Immunology</i> , 1999, 97, 159-165.	4.4	175
388	Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. <i>Nature Medicine</i> , 1999, 5, 444-447.	30.7	233
389	Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 262-268.	2.0	68
390	IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells. <i>Journal of Immunology</i> , 1999, 162, 299-304.	0.8	60
391	Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. <i>Clinical Cancer Research</i> , 1999, 5, 9-16.	7.0	237
392	CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkinâ€™s lymphoma. <i>Bone Marrow Transplantation</i> , 1998, 21, 1177-1181.	2.4	33
393	IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops. <i>Oncogene</i> , 1998, 16, 2503-2512.	5.9	41
394	TAL1 expression does not occur in the majority of T-ALL blasts. <i>British Journal of Haematology</i> , 1998, 102, 449-457.	2.5	18
395	Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 11348-11353.	7.1	51
396	High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.. <i>Journal of Clinical Oncology</i> , 1998, 16, 13-18.	1.6	174

#	ARTICLE	IF	CITATIONS
397	Further Analysis of Interleukin-2 Receptor Subunit Expression on the Different Human Peripheral Blood Mononuclear Cell Subsets. <i>Blood</i> , 1998, 91, 165-172.	1.4	48
398	Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant. <i>Blood</i> , 1998, 91, 3671-3680.	1.4	304
399	Altered Interleukin-12 Responsiveness in Th1 and Th2 Cells Is Associated With the Differential Activation of STAT5 and STAT1. <i>Blood</i> , 1998, 91, 1341-1354.	1.4	73
400	Efficacy and Costs of Granulocyte Colony-Stimulating Factor in Allogeneic T-Cell Depleted Bone Marrow Transplantation. <i>Blood</i> , 1998, 92, 2725-2729.	1.4	29
401	Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.. <i>Journal of Clinical Investigation</i> , 1998, 102, 561-575.	8.2	40
402	Further Analysis of Interleukin-2 Receptor Subunit Expression on the Different Human Peripheral Blood Mononuclear Cell Subsets. <i>Blood</i> , 1998, 91, 165-172.	1.4	2
403	Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant. <i>Blood</i> , 1998, 91, 3671-3680.	1.4	11
404	Efficacy and Costs of Granulocyte Colony-Stimulating Factor in Allogeneic T-Cell Depleted Bone Marrow Transplantation. <i>Blood</i> , 1998, 92, 2725-2729.	1.4	0
405	Further analysis of interleukin-2 receptor subunit expression on the different human peripheral blood mononuclear cell subsets. <i>Blood</i> , 1998, 91, 165-72.	1.4	15
406	Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. <i>Blood</i> , 1998, 91, 3671-80.	1.4	75
407	Expression of the IL-2 receptor gamma subunit in resting human CD4 T lymphocytes: mRNA is constitutively transcribed and the protein stored as an intracellular component. <i>International Immunology</i> , 1997, 9, 573-580.	4.0	34
408	Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.. <i>Journal of Clinical Oncology</i> , 1997, 15, 723-734.	1.6	74
409	Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Dose Intensification With Granulocyte Colony-Stimulating Factor Markedly Depletes Stem Cell Reserve for Autologous Bone Marrow Transplantation. <i>Blood</i> , 1997, 90, 4996-5001.	1.4	45
410	CD6-Depleted Allogeneic Bone Marrow Transplantation for Acute Leukemia in First Complete Remission. <i>Blood</i> , 1997, 89, 3039-3047.	1.4	90
411	Altered Tyrosine Phosphorylation Via the Very Late Antigen (VLA)β21 Integrin Stimulation Is Associated With Impaired T-Cell Signaling Through VLA-4 After Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 1997, 90, 4222-4229.	1.4	3
412	Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. <i>British Journal of Haematology</i> , 1997, 97, 409-417.	2.5	103
413	Interferon-γ and interleukin-4 regulate T cell interleukin-12 responsiveness through the differential modulation of high-affinity interleukin-12 receptor expression. <i>European Journal of Immunology</i> , 1997, 27, 647-652.	2.9	76
414	Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.. <i>Journal of Clinical Investigation</i> , 1997, 100, 855-866.	8.2	94

#	ARTICLE	IF	CITATIONS
415	B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues.. Journal of Clinical Investigation, 1997, 100, 3140-3148.	8.2	224
416	Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Dose Intensification With Granulocyte Colony-Stimulating Factor Markedly Depletes Stem Cell Reserve for Autologous Bone Marrow Transplantation. Blood, 1997, 90, 4996-5001.	1.4	1
417	CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood, 1997, 89, 3039-47.	1.4	22
418	Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clinical Cancer Research, 1997, 3, 409-17.	7.0	365
419	CD2-CD58 Interaction and the Control of T-Cell Interleukin-12 Responsiveness.. Annals of the New York Academy of Sciences, 1996, 795, 71-81.	3.8	18
420	Chapter 10 Immunity to cancer. Advances in Oncobiology, 1996, 1, 207-219.	0.0	0
421	Transcript synthesis and surface expression of the interleukin-2 receptor (alpha-, beta-, and gamma) in T cells. Journal of Immunology, 1996, 156, 107-114.	2.4	41
422	Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood, 1996, 88, 2228-2235.	1.4	197
423	Defective activation of mitogen-activated protein kinase after allogeneic bone marrow transplantation. Blood, 1996, 88, 2334-2341.	1.4	16
424	High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood, 1996, 88, 2780-2786.	1.4	210
425	TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood, 1996, 88, 4252-4258.	1.4	238
426	R24 anti-GD3 ganglioside antibody can induce co-stimulation and prevent the induction of alloantigen-specific T cell clonal anergy. European Journal of Immunology, 1996, 26, 2149-2154.	2.9	11
427	Evidence against T cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expression. Immunology, 1996, 87, 402-407.	4.4	14
428	PREVENTION OF TRANSMISSION OF HEPATITIS C VIRUS IN BONE MARROW TRANSPLANTATION BY TREATING THE DONOR WITH INTERFERON-1. Transplantation, 1996, 62, 1358-1360.	1.0	37
429	Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment. Oncologist, 1996, 1, 88-97.	3.7	82
430	Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. American Journal of Pathology, 1996, 148, 847-53.	3.8	54
431	Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Experimental Hematology, 1996, 24, 406-15.	0.4	290
432	Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T cell activation by IL-12. Journal of Immunology, 1996, 157, 1886-93.	0.8	55

#	ARTICLE	IF	CITATIONS
433	Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. <i>Blood</i> , 1996, 88, 2228-35.	1.4	33
434	High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. <i>Blood</i> , 1996, 88, 2780-6.	1.4	22
435	Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals. <i>Natural Immunity</i> , 1996, 15, 213-26.	0.1	29
436	Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. <i>Clinical Cancer Research</i> , 1996, 2, 493-9.	7.0	28
437	Interleukin 2 signaling involves the phosphorylation of Stat proteins.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 7779-7783.	7.1	113
438	Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation. <i>Journal of Clinical Apheresis</i> , 1995, 10, 139-143.	1.3	5
439	Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin. <i>Journal of Clinical Immunology</i> , 1995, 15, 51-57.	3.8	16
440	Phosphorylation of src Family lck Tyrosine Kinase Following Interleukin-12 Activation of Human Natural Killer Cells. <i>Cellular Immunology</i> , 1995, 165, 211-216.	3.0	33
441	Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1995, 85, 1132-1137.	1.4	21
442	Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial.. <i>Journal of Clinical Oncology</i> , 1995, 13, 239-250.	1.6	102
443	CD2 regulates responsiveness of activated T cells to interleukin 12.. <i>Journal of Experimental Medicine</i> , 1995, 182, 721-731.	8.5	84
444	Monoclonal Antibody-Purged Bone Marrow Transplantation Therapy for Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1995, 17, 87-93.	1.3	32
445	Functional Consequences of APO-1/Fas (CD95) Antigen Expression by Normal and Neoplastic Hematopoietic Cells. <i>Leukemia and Lymphoma</i> , 1995, 17, 51-61.	1.3	93
446	Interleukin-12 induces tyrosine phosphorylation and activation of 44-kD mitogen-activated protein kinase in human T cells. <i>Blood</i> , 1994, 83, 184-190.	1.4	46
447	Effect of low-dose interleukin-2 on disease relapse after T-cell- depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1994, 84, 964-971.	1.4	146
448	Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. <i>Blood</i> , 1994, 84, 2109-2114.	1.4	34
449	Tumor immunity: will new keys unlock the door?. <i>Journal of Clinical Oncology</i> , 1994, 12, 237-238.	1.6	10
450	Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells.. <i>Journal of Experimental Medicine</i> , 1994, 180, 241-251.	8.5	127

#	ARTICLE	IF	CITATIONS
451	Prognostic Significance of the Surface Antigens Expressed by Leukemic Cells. <i>Leukemia and Lymphoma</i> , 1994, 13, 15-22.	1.3	1
452	Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. <i>Science</i> , 1994, 266, 1039-1042.	12.6	303
453	Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. <i>International Journal of Cancer</i> , 1994, 57, 57-59.	5.1	24
454	Preparation and characterization of interleukin-2-gelonin conjugates made using different crosslinking reagents. <i>Bioconjugate Chemistry</i> , 1994, 5, 88-97.	3.6	21
455	THE PHENOTYPE AND RECONSTITUTION OF IMMUNOREGULATORY T CELL SUBSETS AFTER T CELL-DEPLETED ALLOGENEIC AND AUTOLOGOUS BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 1994, 57, 1465-1473.	1.0	15
456	THE EFFECT OF MINOR ABO MISMATCHES ON THE INCIDENCE OF GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 1994, 57, 780.	1.0	9
457	THE PHENOTYPE AND RECONSTITUTION OF IMMUNOREGULATORY T CELL SUBSETS AFTER T CELL-DEPLETED ALLOGENEIC AND AUTOLOGOUS BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 1994, 57, 1465-1473.	1.0	38
458	Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation.. <i>Journal of Clinical Investigation</i> , 1994, 94, 481-488.	8.2	13
459	Effect of low-dose interleukin-2 on disease relapse after T-cell- depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1994, 84, 964-971.	1.4	4
460	Interleukin-12 induces tyrosine phosphorylation and activation of 44-kD mitogen-activated protein kinase in human T cells. <i>Blood</i> , 1994, 83, 184-190.	1.4	3
461	The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation. <i>Transplantation</i> , 1994, 57, 1465-73.	1.0	5
462	Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1994, 84, 964-71.	1.4	36
463	Clinical Significance of bcr-abl Gene Rearrangement Detected by the Polymerase Chain Reaction After Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia. <i>Leukemia and Lymphoma</i> , 1993, 10, 1-8.	1.3	13
464	Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. <i>Blood</i> , 1993, 81, 1651-1657.	1.4	55
465	Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. <i>Blood</i> , 1993, 82, 2790-2796.	1.4	66
466	Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. <i>Blood</i> , 1993, 81, 1651-1657.	1.4	0
467	Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. <i>Blood</i> , 1993, 82, 2790-2796.	1.4	1
468	Costimulatory signals are required for optimal proliferation of human natural killer cells. <i>Journal of Immunology</i> , 1993, 150, 1705-14.	0.8	75

#	ARTICLE	IF	CITATIONS
469	Fc gamma RIIIA-mediated signaling involves src-family lck in human natural killer cells. <i>Journal of Immunology</i> , 1993, 151, 6794-800.	0.8	45
470	Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF.. <i>Journal of Experimental Medicine</i> , 1992, 175, 779-788.	8.5	337
471	Immune-Mediated Cytopenia following Bone Marrow Transplantation Case Reports and Review of the Literature. <i>Medicine (United States)</i> , 1992, 71, 73-83.	1.0	38
472	Changing antigen receptor gene rearrangements in a case of early pre-B cell leukemia: evidence for a tumor progenitor cell with stem cell features and implications for monitoring residual disease. <i>Blood</i> , 1992, 79, 481-488.	1.4	30
473	Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1992, 79, 517-526.	1.4	191
474	Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. <i>Blood</i> , 1992, 79, 576-585.	1.4	166
475	Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor alpha beta lineage. <i>Blood</i> , 1992, 80, 1511-1520.	1.4	52
476	Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. <i>European Journal of Immunology</i> , 1992, 22, 1-6.	2.9	122
477	Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1992, 79, 517-526.	1.4	3
478	Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. <i>Blood</i> , 1992, 79, 576-585.	1.4	1
479	Changing antigen receptor gene rearrangements in a case of early pre-B cell leukemia: evidence for a tumor progenitor cell with stem cell features and implications for monitoring residual disease. <i>Blood</i> , 1992, 79, 481-488.	1.4	0
480	Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor alpha beta lineage. <i>Blood</i> , 1992, 80, 1511-1520.	1.4	1
481	Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1992, 79, 517-26.	1.4	46
482	Monoclonal anti-T cell (T12) antibody treatment of graft-versus-host disease in severe combined immunodeficiency: targeting of antibody and activation of complement on CD8+ cytotoxic T cell surfaces. <i>Journal of Allergy and Clinical Immunology</i> , 1991, 87, 1029-1033.	2.9	4
483	Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. <i>Blood</i> , 1991, 77, 2524-2529.	1.4	168
484	Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. <i>Blood</i> , 1991, 77, 2404-2412.	1.4	53
485	Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. <i>Blood</i> , 1991, 77, 712-720.	1.4	94
486	Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. <i>Blood</i> , 1991, 78, 2759-2767.	1.4	97

#	ARTICLE	IF	CITATIONS
487	HEPATIC DYSFUNCTION FOLLOWING T-CELL-DEPLETED ALLOGENEIC BONE MARROW TRANSPLANTATION. Transplantation, 1991, 52, 1014-1019.	1.0	54
488	PROPHYLAXIS OF BACTERIAL INFECTIONS WITH CIPROFLOXACIN IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION. Transplantation, 1991, 51, 630-635.	1.0	67
489	Immunologic Purging of Marrow Assessed by PCR before Autologous Bone Marrow Transplantation for B-Cell Lymphoma. New England Journal of Medicine, 1991, 325, 1525-1533.	27.0	678
490	Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer. New England Journal of Medicine, 1991, 324, 1773-1778.	27.0	481
491	Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood, 1991, 77, 712-720.	1.4	1
492	Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood, 1991, 77, 2404-2412.	1.4	1
493	Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood, 1991, 77, 2524-2529.	1.4	1
494	Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood, 1991, 78, 2759-2767.	1.4	0
495	Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood, 1991, 78, 2759-67.	1.4	9
496	Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood, 1991, 77, 2404-12.	1.4	7
497	Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2274-2278.	7.1	161
498	Differential expression of CD8 ⁺ and CD8 ⁺ associated with MHC-restricted and non-MHC-restricted cytolytic effector cells. Cellular Immunology, 1990, 131, 352-365.	3.0	76
499	Comparative activities of rabbit complements of different ages using an in-vitro marrow purging model. Leukemia Research, 1990, 14, 407-416.	0.8	17
500	A chronic ?postinfectious? fatigue syndrome associated with benign lymphoproliferation, B-cell proliferation, and active replication of human herpesvirus-6. Journal of Clinical Immunology, 1990, 10, 335-344.	3.8	25
501	Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood, 1990, 75, 296-304.	1.4	99
502	Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood, 1990, 75, 2076-2084.	1.4	65
503	Biology and clinical relevance of human natural killer cells. Blood, 1990, 76, 2421-2438.	1.4	869
504	Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.. Journal of Experimental Medicine, 1990, 171, 1509-1526.	8.5	418

#	ARTICLE	IF	CITATIONS
505	Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1990, 75, 2076-2084.	1.4	27
506	Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. <i>Blood</i> , 1990, 75, 296-304.	1.4	0
507	Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytotoxicity. <i>Journal of Immunology</i> , 1990, 145, 3194-201.	0.8	167
508	Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1990, 75, 2076-84.	1.4	16
509	Biology and clinical relevance of human natural killer cells. <i>Blood</i> , 1990, 76, 2421-38.	1.4	248
510	Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 1990, 6, 329-31.	2.4	15
511	Expression of Epstein-Barr Virus Transformation-Associated Genes in Tissues of Patients with EBV Lymphoproliferative Disease. <i>New England Journal of Medicine</i> , 1989, 321, 1080-1085.	27.0	804
512	The Role of Natural Killer Cells in Immune Surveillance. <i>New England Journal of Medicine</i> , 1989, 320, 1748-1749.	27.0	62
513	Clonal evidence for the induction of NKH1 on activated human thymocytes. <i>European Journal of Immunology</i> , 1989, 19, 1735-1739.	2.9	9
514	CD3-negative natural killer cells express γ TCR as part of a novel molecular complex. <i>Nature</i> , 1989, 341, 159-162.	27.8	202
515	Autologous bone marrow transplantation therapy for multiple myeloma. <i>European Journal of Haematology</i> , 1989, 43, 157-163.	2.2	5
516	Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function. <i>Blood</i> , 1989, 74, 2203-2211.	1.4	30
517	Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 1989, 4, 239-45.	2.4	22
518	Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function. <i>Blood</i> , 1989, 74, 2203-2211.	1.4	2
519	Characterization of Functional Surface Structures on Human Natural Killer Cells. <i>Advances in Immunology</i> , 1988, 42, 181-211.	2.2	163
520	Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988, 85, 4819-4823.	7.1	164
521	Identification of a second transforming gene, <i>rasn</i> , in a human multiple myeloma line with a rearranged <i>c-myc</i> allele. <i>Blood</i> , 1988, 72, 1163-1167.	1.4	17
522	Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complement. <i>Cancer Treatment and Research</i> , 1988, 38, 265-283.	0.5	2

#	ARTICLE	IF	CITATIONS
523	Induction of natural killer effectors from human thymus with recombinant IL-2. Journal of Immunology, 1988, 140, 3660-7.	0.8	35
524	Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood, 1988, 72, 1163-1167.	1.4	8
525	Prolonged Disease-Free Survival after Autologous Bone Marrow Transplantation in Patients with Non-Hodgkin's Lymphoma with a Poor Prognosis. New England Journal of Medicine, 1987, 316, 1499-1505.	27.0	264
526	Identification and cloning of a prethymic precursor T lymphocyte from a population of common acute lymphoblastic leukemia antigen (CALLA)-positive fetal bone marrow cells.. Journal of Experimental Medicine, 1987, 165, 1749-1754.	8.5	23
527	Epstein-Barr Virus-Transformed B-Cell Line (DV-1) Derived from Bone Marrow of a Patient with Severe Combined Immunodeficiency and Immunoblastic Lymphoma. Pediatric Research, 1987, 21, 331-337.	2.3	9
528	Lymphoma with clonal T-cell receptor gene rearrangement in a 25-year survivor of Hodgkin's disease. Cancer, 1987, 60, 2213-2218.	4.1	3
529	Lymphokine-activated killer cell activity. Trends in Immunology, 1987, 8, 178-181.	7.5	229
530	Enhancement of natural killer function through activation of the T11 E rosette receptor.. Journal of Clinical Investigation, 1987, 79, 305-308.	8.2	44
531	Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood, 1987, 69, 597-604.	1.4	46
532	Activation of Natural Killer Function Through the T11/E Rosette Receptor. Hamatologie Und Bluttransfusion, 1987, 31, 347-350.	0.0	1
533	Monoclonal-Antibody-Purged Autologous Bone Marrow Transplantation for Relapsed Non-T-Cell Acute Lymphoblastic Leukemia in Childhood. Hamatologie Und Bluttransfusion, 1987, 31, 67-74.	0.0	2
534	Ultrastructural evidence that the granules of human natural killer cell clones store membrane in a nonbilayer phase. American Journal of Pathology, 1987, 127, 305-16.	3.8	7
535	Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. Journal of Immunology, 1987, 139, 3306-13.	0.8	180
536	Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood, 1986, 67, 722-728.	1.4	138
537	Clonal Analysis of Natural Killer Cell Lineage and Function1. , 1986, , 19-33.		0
538	DEPLETION OF T CELLS FROM HUMAN BONE MARROW USING MONOCLONAL ANTIBODIES AND RABBIT COMPLEMENT. Transplantation, 1986, 42, 73-79.	1.0	29
539	Implications for Monitoring Natural Killer Responses following Allogeneic Bone Marrow Transplantation. Transplantation, 1986, 42, 252-256.	1.0	13
540	Function of the LFA-1 and T4 molecules in the direct activation of resting human B lymphocytes by T lymphocytes. European Journal of Immunology, 1986, 16, 1539-1543.	2.9	45

#	ARTICLE	IF	CITATIONS
541	Antigenic heterogeneity among burkitt's lymphoma cells surviving treatment with monoclonal antibody and complement. <i>Leukemia Research</i> , 1986, 10, 35-42.	0.8	9
542	A subset of natural killer cells in peripheral blood displays a mature T cell phenotype.. <i>Journal of Experimental Medicine</i> , 1986, 164, 351-356.	8.5	207
543	Expression of the NKTa clonotype in a series of human natural killer clones with identical cytotoxic specificity.. <i>Journal of Experimental Medicine</i> , 1986, 163, 812-825.	8.5	31
544	NK-Associated and LFA-1 Antigens: Phenotypic and Functional Studies Utilizing Human NK Clones. , 1986, , 133-144.		1
545	In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates.. <i>Journal of Clinical Investigation</i> , 1986, 77, 977-984.	8.2	58
546	In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. Delivery of ribosome-inactivating proteins to spleen and lymph node T cells.. <i>Journal of Clinical Investigation</i> , 1986, 78, 666-673.	8.2	21
547	Monoclonal Antibody Purged Autologous Bone Marrow Transplantation for Relapsed Non T-Cell Acute Lymphoblastic Leukemia. , 1986, , 266-274.		2
548	Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. <i>Nature</i> , 1985, 317, 428-430.	27.8	288
549	Specific release of proteoglycans from human natural killer cells during target lysis. <i>Nature</i> , 1985, 318, 289-291.	27.8	148
550	Functional surface structures on human natural killer cells. <i>Klinische Wochenschrift</i> , 1985, 63, 1189-1200.	0.6	6
551	Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. <i>Blood</i> , 1985, 65, 1064-1070.	1.4	68
552	Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. <i>Science</i> , 1985, 228, 1540-1543.	12.6	161
553	Epsteinâ€“Barr Virusâ€“Associated B-Cell Proliferations of Diverse Clonal Origins after Bone Marrow Transplantation in a 12-Year-Old Patient with Severe Combined Immunodeficiency. <i>New England Journal of Medicine</i> , 1985, 312, 1151-1159.	27.0	207
554	Proteoglycans in cell-mediated cytotoxicity. Identification, localization, and exocytosis of a chondroitin sulfate proteoglycan from human cloned natural killer cells during target cell lysis.. <i>Journal of Experimental Medicine</i> , 1985, 162, 1771-1787.	8.5	149
555	Activation of a novel human transforming gene, ret, by DNA rearrangement. <i>Cell</i> , 1985, 42, 581-588.	28.9	730
556	Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes.. <i>Journal of Clinical Investigation</i> , 1985, 75, 932-943.	8.2	259
557	IDENTIFICATION AND CHARACTERIZATION OF HUMAN LEUKEMIA ASSOCIATED ANTIGENS11Supported in part by NIH grant CA 34183.. , 1985, , 85-95.		0
558	Transplantation with anti-B1 monoclonal antibody and complement treated autologous bone marrow for relapsed B-cell non-Hodgkinâ€“TMs lymphoma. , 1985, , 537-547.		1

#	ARTICLE	IF	CITATIONS
559	Serotherapy and Bone Marrow Transplantation. , 1985, , 493-504.		1
560	Orderly expression of B cell antigens during the in vitro differentiation of nonmalignant human pre-B cells. Journal of Immunology, 1985, 135, 1746-51.	0.8	43
561	In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates: I. Effects of anti-T11 antibodies on the circulating T cell pool. Blood, 1985, 66, 961-6.	1.4	6
562	The role of interleukin 2 and T11 E rosette antigen in activation and proliferation of human NK clones. Journal of Immunology, 1985, 135, 672-8.	0.8	38
563	Functional characterization of LFA-1 antigens in the interaction of human NK clones and target cells. Journal of Immunology, 1985, 135, 1020-5.	0.8	86
564	Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Research, 1985, 45, 499-503.	0.9	77
565	Natural killer-like function of activated T lymphocytes: Differential blocking effects of monoclonal antibodies specific for a 90-kDa clonotypic structure. Cellular Immunology, 1984, 86, 381-392.	3.0	14
566	Identification of a 140-kDa activation antigen as a target structure for a series of human cloned natural killer cell lines. European Journal of Immunology, 1984, 14, 844-852.	2.9	45
567	Clinical Applications of Monoclonal Antibodies in Acute Leukemia. Annals of the New York Academy of Sciences, 1984, 428, 308-317.	3.8	6
568	Application of Monoclonal Antibodies to Autologous Bone Marrow Transplantation. , 1984, , 185-206.		5
569	Autologous Bone Marrow Transplantation in Calla Positive Acute Lymphoblastic Leukemia. , 1984, , 255-264.		3
570	Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow. Blood, 1984, 64, 662-6.	1.4	8
571	Phenotypic and functional heterogeneity of human cloned natural killer cell lines. Nature, 1983, 301, 158-160.	27.8	189
572	Identification and molecular cloning of the human Blym transforming gene activated in Burkitt's lymphomas. Nature, 1983, 305, 112-116.	27.8	194
573	Expression of MY7 antigen on myeloid precursor cells. International Journal of Cell Cloning, 1983, 1, 33-48.	1.6	77
574	Acute lymphoblastic leukemia: Use of immune markers in diagnosis, prognosis and therapy. Clinical Biochemistry, 1983, 16, 357.	1.9	0
575	Interferon-Induced Changes in Expression of Antigens Defined by Monoclonal Antibodies on Malignant and Nonmalignant Mononuclear Hematopoietic Cells. Journal of Interferon Research, 1983, 3, 199-210.	1.2	9
576	Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA).. Journal of Experimental Medicine, 1983, 157, 114-129.	8.5	97

#	ARTICLE	IF	CITATIONS
577	Identification of a clonally restricted 90 kD heterodimer on two human cloned natural killer cell lines. Its role in cytotoxic effector function.. Journal of Experimental Medicine, 1983, 158, 1547-1560.	8.5	116
578	Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts. Blood, 1983, 61, 628-639.	1.4	228
579	In Vitro Treatment with Monoclonal Antibody Prior to Autologous Bone Marrow Transplantation in Acute Lymphoblastic Leukemia. Hamatologie Und Bluttransfusion, 1983, 28, 117-123.	0.0	1
580	Use of monoclonal antibodies in autologous and allogeneic bone marrow transplantation. Clinics in Haematology, 1983, 12, 813-832.	2.3	19
581	Expression of Normal Differentiation Antigens on Human Leukemias and Lymphomas. , 1983, , 45-56.		0
582	Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Research, 1983, 43, 1389-94.	0.9	72
583	Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts. Blood, 1983, 61, 628-39.	1.4	44
584	AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN CALLA-POSITIVE ACUTE LYMPHOBLASTIC LEUKAEMIA AFTER IN-VITRO TREATMENT WITH J5 MONOCLONAL ANTIBODY AND COMPLEMENT. Lancet, The, 1982, 320, 60-63.	13.7	224
585	Cell-Surface Antigens in Acute Leukemia. , 1982, , 1-21.		3
586	Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia.. Journal of Clinical Investigation, 1982, 70, 433-442.	8.2	90
587	Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood, 1982, 59, 1-11.	1.4	223
588	Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen. Cancer Research, 1982, 42, 457-64.	0.9	88
589	Generation of a cloned NK cell line derived from the "null cell" fraction of human peripheral blood. Journal of Immunology, 1982, 129, 1299-305.	0.8	67
590	Expression of a 26,000-dalton glycoprotein on activated human T cells. Cellular Immunology, 1981, 64, 192-199.	3.0	68
591	Human cell lines express multiple populations of Ia-like molecules. Human Immunology, 1981, 3, 67-76.	2.4	14
592	Comparative expression of T9, T10, and Ia antigens on activated human T cell subsets. Human Immunology, 1981, 3, 247-259.	2.4	149
593	Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood, 1981, 57, 1105-1110.	1.4	206
594	Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood, 1981, 58, 141-152.	1.4	292

#	ARTICLE	IF	CITATIONS
595	Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. Blood, 1981, 58, 333-336.	1.4	35
596	Surface antigens on malignant Sezary and T-CLL cells correspond to those of mature T cells. Blood, 1981, 57, 526-530.	1.4	128
597	Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood, 1981, 58, 648-652.	1.4	200
598	801 ABSENCE OF COMMON ALL ANTIGEN ON NORMAL PLURIPOTENTIAL MYELOID, ERYTHROID AND GRANULOCYTE PROGENITORS. Pediatric Research, 1981, 15, 576-576.	2.3	0
599	Expression of normal monocyte-macrophage differentiation antigens on HL60 promyelocytes undergoing differentiation induced by leukocyte-conditioned medium or phorbol diester. Leukemia Research, 1981, 5, 491-495.	0.8	88
600	Comparative Antigenic Phenotypes of Normal and Leukemic Hemopoietic Precursor Cells Analysed with a "Library" of Monoclonal Antibodies. Hamatologie Und Bluttransfusion, 1981, 26, 296-304.	0.0	16
601	A unique cell surface antigen identifying lymphoid malignancies of B cell origin.. Journal of Clinical Investigation, 1981, 67, 134-140.	8.2	368
602	Expression of myeloid differentiation antigens on normal and malignant myeloid cells.. Journal of Clinical Investigation, 1981, 68, 932-941.	8.2	491
603	Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood, 1981, 58, 141-52.	1.4	44
604	Fate of a common acute lymphoblastic leukemia antigen during modulation by monoclonal antibody. Journal of Immunology, 1981, 126, 540-4.	0.8	34
605	Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. Blood, 1981, 58, 333-6.	1.4	3
606	Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood, 1981, 58, 648-52.	1.4	43
607	Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. Progress in Hematology, 1981, 12, 187-225.	0.3	27
608	Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. Blood, 1981, 58, 333-336.	1.4	0
609	A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature, 1980, 283, 583-585.	27.8	700
610	Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood, 1980, 55, 395-402.	1.4	208
611	Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in vitro. Journal of Immunology, 1980, 125, 1506-14.	0.8	91
612	Human leukemia-associated antigen: relation to a family of surface glycoproteins. Journal of Immunology, 1980, 124, 2794-9.	0.8	28

#	ARTICLE	IF	CITATIONS
613	Leukemia-associated antigens in ALL. Blood, 1979, 54, 1240-1248.	1.4	69
614	Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation stimuli required for expression.. Journal of Experimental Medicine, 1979, 150, 1472-1482.	8.5	610
615	Leukemia-associated antigens in ALL. Blood, 1979, 54, 1240-1248.	1.4	1
616	Leukemia-associated antigens in ALL. Blood, 1979, 54, 1240-8.	1.4	17
617	Systemic Mastocytosis Associated With Presence of Rheumatoid Factor. JAMA - Journal of the American Medical Association, 1976, 235, 1586.	7.4	3